This study analyzed bioactive-phytoconstituents of the n-hexane fraction of Cassia fistula L. fruit extract using HPLC-DAD and investigated its anticancer potential using several biochemical and molecular methods, such as cell viability, induction of apoptosis, aberrant cell cycle progression, changes in the expression of pro/anti-apoptotic genes, and others. HPLC analysis revealed the possible presence of quercetin and kaempferol alongside catechin, rutin, caffeic acid, orientin, and iso-orientin. We observed a dose-dependent decline in cell viability in MCF-7 cell line with IC 50 concentration of 99.7 μg/mL. The morphological alteration and wound healing assay indicated the presence of morphologically altered cells and non-significant closure of the wound in the IC50 treated cells. Moreover, flow cytometry investigations revealed rise in apoptotic cells (from 5% to 29%), increased reactive oxygen species (ROS) production (+17%), mitochondrial membrane potential (MMP) loss (from 23% to 13%), and cell cycle perturbation characterized by accumulation of cells in both G 0 /G 1 (from 17.2% to 37.4%) and G2/M-phases (from 11.6% control 24%). Reverse transcription polymerase chain reaction (RT-PCR) revealed the upregulation of the p53 (4-fold) and Bax (4.5-fold) genes, as well as downregulation of Bcl-2 (2.5-fold) gene. Our findings highlight the anticancer efficacy of the n-hexane fruit extract of C . fistula L . However, further validation is required in a suitable in-vivo /xenograft model so that this potent plant can be exploited clinically, especially against breast cancer.
No takes yet. Share an insight, caveat, or question.
Ahmad et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: